Skip to content

Trial · Interventional

WithdrawnPhase 4Registry data

CMAB vs IMAB in Metastatic Prostate Cancer

NCTNCT00255268 (opens ClinicalTrials.gov in a new tab)Other idD6876L00010
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Withdrawn
Phase
Phase 4
Enrollment
15 participants (estimated)
Sponsor
AstraZeneca · Industry
Design
Randomized · Open label (no masking)
Countries
1 country

Mexico

Start
Aug 2004
Primary completion
Not stated
Completion
Not stated
First posted
18 Nov 2005 (estimated)
Last update posted
28 Aug 2007 (estimated)
Conditions
Metastatic Prostate Cancer

Timeline

1 trial · 1 stopped early

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20042005
  1. Ph 4

    CMAB vs IMAB in Metastatic Prostate Cancer

    NCT00255268

    Start Aug 2004

    Withdrawn

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

To evaluate the efficacy, safety and survival of two treatment regimens: Continuous Intermittent Maximum Androgen Blockade, using goserelin and bicalutamide in patients with prostate cancer. Primary endpoint is time to progression. Fifteen patients will be evaluated. QoL evaluation is also included.

Interventions

  • GoserelinDrug
  • BicalutamideDrug

Arms0

The registry lists no arms for this trial.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Time to progression

Secondary outcomes(2)

  1. Safety

  2. Quality of Life

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
Male
Age
from 18 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Histological diagnosis of D2 of Adenocarcinoma, * Naivety to treatment * Valuable bone metastasis Exclusion Criteria: * Hematological, liver or renal toxicity Grade IV * Severe and active infections

PepBank is a research reference. Talk to a doctor before you use any peptide.